Pharmacogenetic Response to Chemotherapy Induction for ORL Cancers (APPROCHE ORL)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nīmes
ClinicalTrials.gov Identifier:
NCT01104714
First received: April 14, 2010
Last updated: May 13, 2014
Last verified: May 2014
  Purpose

The purpose of this study is to determine if there is a correlation between tumor response after 3 doses of chemotherapy by induction using Docetaxel, Cisplatine and 5-Fluorouracile for advanced stage epidermoid carcinomas of the upper aero digestive tract and the presence of one or a combination of 3 genetic polymorphisms and/or 5 intra-tumoral transcriptional modifications.


Condition
Carcinoma, Squamous Cell
Mouth Neoplasms
Oropharyngeal Neoplasms
Laryngeal Neoplasms
Hypopharyngeal Neoplasms

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pharmacogenetic and Pharmacokinetic Aspects of the Response to Chemotherapy Induction Using Docetaxel, Cisplatin and 5-Fluorouracile (TPF)in ORL Cancers

Resource links provided by NLM:


Further study details as provided by Centre Hospitalier Universitaire de Nīmes:

Primary Outcome Measures:
  • %change in tumor volume before and after chemotherapy (baseline versus 62 days) [ Time Frame: 62 days ] [ Designated as safety issue: No ]
    Tumor volume is calculated according to Labadie et al 2000


Biospecimen Retention:   Samples With DNA

Surplus blood, tumor tissue from biopsies, and DNA will be stocked in the Biothèque of the Nîmes University Hospital


Enrollment: 90
Study Start Date: April 2010
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
All patients
As the trial progresses, patients will be classified as either chemotherapy responders or non-responders.

  Eligibility

Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The patients included in this study have been diagnosed with an advanced stage squamous cell carcinoma in the buccal, oropharyngeal, laryngeal or hypopharyngeal areas.

Criteria

Inclusion Criteria:

  • Squamous cell carcinoma originating in the mouth, oropharynx, larynx or hypopharynx has been histologically documented.
  • The disease is at one of the following UICC 2002 stages, regardless of ganglion status: T3 MO or T4 MO
  • Treatment via chemotherapy, radiotherapy or surgery (except for the diagnostic biopsy) has not started
  • The pluridisciplinary committee as ruled out surgical options for technical or functional reasons
  • Absence of distant metastases
  • OMS general health status between 0 and 2
  • Patient has given informed consent
  • Patient is affiliated with a social security system

Exclusion Criteria:

  • Undifferentiated squamous cell carcinomas in the nasopharynx (UCNT)
  • Another cancer priorly treated with one of the following chemotherapies: Docetaxel, Cisplatin, 5-Fluorouracile
  • Creatininemia > 2 mg/dl and/or creatinine clearance < 60ml/min
  • Patient under guardianship
  • Presence of another severe pathology including:

    • severe or chronic cardiac, renal and/or hepatic insufficiencies
    • severe medullary hypoplasia
    • severe autoimmune disease
    • psychosis or senility
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01104714

Locations
France
CH d'Alès
Alès, France, 30103
CHU de Bordeaux - Groupe Hospitalier Saint-André
Bordeaux, France, 33075
CHU de Bordeaux - Groupe Hospitalier Pellegrin
Bordeaux, France, 33076
CHU de Grenoble
Grenoble cedex 09, France, 38043
Centre de Lutte Contre le Cancer - Centre Oscar Lambret
Lille Cedex, France, 59020
CHU de Montpellier - Hôpital Gui de Chauliac
Montpellier cedex 5, France, 34295
Centre Regional de Lutte Contre le Cancer - Val d'Aurelle - Paul Lamarque
Montpellier cedex 5, France, 34298
Centre Antoine Lacassagne
Nice cedex 2, France, 06189
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, France, 30029
CHRU de Toulouse - Hôpital Larrey
Toulouse, France, 31059
Pharmacologie Clinique, expérim. des anticancéreux, CLCC Claudius Regaud
Toulouse, France, 31052
CHRU de Toulouse - Hôpital de Rangueil
Toulouse, France, 31059
Centre de Lutte Contre le Cancer - Institut Claudius Regaud
Toulouse Cedex, France, 31052
CHRU de Toulouse - Hôpital Purpan
Toulouse Cedex 9, France, 31059
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nīmes
Investigators
Principal Investigator: Benjamin Lallemant, MD Centre Hospitalier Universitaire de Nîmes
  More Information

Publications:
Responsible Party: Centre Hospitalier Universitaire de Nīmes
ClinicalTrials.gov Identifier: NCT01104714     History of Changes
Other Study ID Numbers: LOCAL/2008/BL-01, 2008-006874-14
Study First Received: April 14, 2010
Last Updated: May 13, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
France: Committee for the Protection of Personnes

Additional relevant MeSH terms:
Neoplasms
Carcinoma
Carcinoma, Squamous Cell
Hypopharyngeal Neoplasms
Laryngeal Neoplasms
Mouth Neoplasms
Oropharyngeal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Laryngeal Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Mouth Diseases

ClinicalTrials.gov processed this record on July 29, 2014